cbdMD rises on research collab to test cannabinoids for therapeutic use

** Shares of cannabis products maker  YCBD.A  up 1% at $2.8;
among biggest pct gainers across U.S. exchanges
    ** Co says it started talks with a cannabinoid research
institute to identify novel cannabinoids for therapeutic use;
expects to start studies by Fall of 2021  urn:newsml:reuters.com:*:nBwn2fpVa
    ** Also expects to identify dietary supplement applications
through this process
    ** Following this, YCBD will perform the requisite
toxicological studies with testing co Ion Tox to support safety
data, which in turn will help support preclinical trials in
humans to test the therapies
    ** Co started first phase of its study in animals in Fall of
2020; second phase is now underway to identify promising
cannabinoids for both human and pet drug therapies
    ** Stock down 5% YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com))

Recent news on cbdMD

See all news